Syndax Pharmaceuticals, Inc. Increase (Decrease) in Contract with Customer, Liability
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-02-27
- Syndax Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-09-30 was -$12.38M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2021-06-30 was -$379.00K.
- Syndax Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$13.13M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was -$1.52M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$12.38M derived: sum of 2 quarters · filed 2024-02-27 | -$12.75M derived: sum of 3 quarters · filed 2024-02-27 | -$13.13M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$12.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$12.75M derived: sum of 2 quarters · filed 2022-11-03 | -$13.13M 10-Q · filed 2022-11-03 | -$13.51M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$379.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$758.00K 10-Q · filed 2022-08-08 | -$1.14M derived: sum of 3 quarters · filed 2023-02-28 | -$1.52M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$379.00K 10-Q · filed 2022-05-09 | -$758.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.14M derived: sum of 3 quarters · filed 2023-02-28 | -$1.52M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$379.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$759.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.14M derived: sum of 3 quarters · filed 2023-02-28 | -$1.52M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$380.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$759.00K derived: sum of 2 quarters · filed 2021-11-15 | -$1.14M 10-Q · filed 2021-11-15 | -$1.52M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$379.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$758.00K 10-Q · filed 2021-08-09 | -$1.14M derived: sum of 3 quarters · filed 2022-03-01 | -$1.52M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$379.00K 10-Q · filed 2021-05-11 | -$758.00K derived: sum of 2 quarters · filed 2022-03-01 | -$1.14M derived: sum of 3 quarters · filed 2022-03-01 | -$1.52M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$379.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$759.00K derived: sum of 2 quarters · filed 2022-03-01 | -$1.14M derived: sum of 3 quarters · filed 2022-03-01 | -$1.52M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$380.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$759.00K derived: sum of 2 quarters · filed 2020-11-05 | -$1.14M 10-Q · filed 2020-11-05 | -$1.52M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | -$379.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$758.00K 10-Q · filed 2020-08-06 | -$1.14M derived: sum of 3 quarters · filed 2021-03-12 | -$1.52M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | -$379.00K 10-Q · filed 2020-05-07 | -$758.00K derived: sum of 2 quarters · filed 2021-03-12 | -$1.14M derived: sum of 3 quarters · filed 2021-03-12 | -$1.52M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | -$379.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$759.00K derived: sum of 2 quarters · filed 2021-03-12 | -$1.14M derived: sum of 3 quarters · filed 2021-03-12 | -$1.52M 10-K · filed 2021-03-12 |
| 2018-09-30 | -$380.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$759.00K derived: sum of 2 quarters · filed 2019-11-07 | -$1.14M 10-Q · filed 2019-11-07 | $2.67M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | -$379.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$758.00K 10-Q · filed 2019-08-07 | $3.05M derived: sum of 3 quarters · filed 2020-03-05 | $2.74M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | -$379.00K 10-Q · filed 2019-05-08 | $3.43M derived: sum of 2 quarters · filed 2020-03-05 | $3.12M derived: sum of 3 quarters · filed 2020-03-05 | |
| 2017-12-31 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $3.50M derived: sum of 2 quarters · filed 2020-03-05 | $2.89M 10-K · filed 2020-03-05 | |
| 2017-09-30 | -$305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$915.00K 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | -$610.00K 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | -$1.22M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |